Skip Navigation


JAC Advance Access originally published online on February 25, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/4/562    most recent
dkh132v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kinloch-de Loes, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinloch-de Loes, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 562-566
© 2004 The British Society for Antimicrobial Chemotherapy

Review

Role of therapeutic vaccines in the control of HIV-1

S. Kinloch-de Loes*

Department of HIV/Thoracic Medicine, Department of Medicine and Department of Immunology and Molecular Pathology, The Royal Free Centre for HIV Medicine, Royal Free Campus, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK

The recent success of highly active antiretroviral therapy (HAART) has altered the prognosis of patients living with HIV-1 infection. However, there are still many challenges to be addressed if we want to develop long-term therapeutic strategies for patients, in both the Western world and resource-poor countries. In this review, the potential role for HIV-1 therapeutic vaccines in the era of HAART will be discussed in the light of the present efforts at developing immune-based therapies to complement antiviral treatment and minimize the duration of exposure to antiviral drugs.

Keywords: immune control, immune-based therapies, HIV, highly active antiretroviral therapy

* Tel: +44-20-7830-2846; Fax: +44-20-7431-0879; E-mail: sabine{at}kinloch.u-net.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.